SYNGR4

Across TCGA pan-cancer cohorts, SYNGR4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYNGR4 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SYNGR4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYNGR4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

HNSC, LAML, and THCA are the cancer types where SYNGR4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.751	<.001	48	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
THCA	OS	Median	All	0.294	0.945	<.001	8	view →
UCEC	DFS	Median	All	1.000	0.625	.037	2	view →
SKCM	DFS	Median	II,III,IV	1.000	0.561	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYNGR4–HNSC (OS)

Open the HNSC breakdown →